|
Characteristic
|
With GnRH N (%)
|
Without GnRH N (%)
|
p value*
|
|---|
|
Age
| | | |
|
Median
|
64
|
63
|
0.79
|
|
Range
|
24–82
|
29–76
| |
|
ECOG PS
| | | |
|
Median
|
1
|
1
|
0.88
|
|
Range
|
0–2
|
0–2
| |
|
Hormone receptor status
| | | |
|
Positive
|
32 (86.5)
|
19 (82.6)
|
0.99
|
|
Negative
|
2 (5.5)
|
2 (8.7)
| |
|
Unknown
|
3 (8)
|
2 (8.7)
| |
|
Adjuvant systemic therapy
| | | |
|
Yes
|
19 (51)
|
10 (43.5)
|
0.60
|
|
No
|
18 (49)
|
13 (56.5)
| |
|
Prior therapy for metastatic disease
| | | |
|
Yes
|
9 (24)
|
7 (30.5)
|
0.99
|
|
No
|
28 (76)
|
16 (69.5)
| |
|
Subsequent lines of CT
| | | |
|
Median
|
1
|
1
|
0.72
|
|
Range
|
1–2
|
1–2
| |
|
Subsequent lines of HT
| | | |
|
Median
|
1
|
1
|
0.85
|
|
Range
|
1–3
|
1–3
| |
|
Dominant disease site
| | | |
|
Viscera
|
24 (64.9)
|
14 (60.8)
| |
|
Bone
|
9 (24.3)
|
8 (34.8)
|
0.98
|
|
Soft-tissue
|
4 (10.8)
|
1 (4.4)
| |
|
Number of disease sites
| | | |
|
1
|
11 (29.7)
|
10 (43.4)
| |
|
2
|
21 (56.7)
|
9 (39.1)
|
0.99
|
|
≥ 3
|
5 (13.6)
|
4 (17.5)
| |
- ECOG PS: Eastern Cooperative Oncology Group Performance Status; CT: chemotherapy; HT: hormone therapy
- *Fisher exact test
